Citations

Clear

554 citation(s) found for "Li, Gerald".

Obstetric Anesthetic Management for Parturients with Hereditary Angioedema: A Case Report and Suggested Protocol
Clark, Kathryn J. , Sviggum, Hans P. , Jacob, Adam K. , Volcheck, Gerald W., Szymanski, Linda M. , Clark, Kathryn , Arendt, Katherine W. , Sharpe, Emily E.

Mayo Clinic

Pain Medicine | December 9, 2020 | Volume: 22 | Issue: 8 | Pages: 1878-1882

10.1093/pm/pnaa457 | PMID 33769522 Get It

Abstract Hereditary angioedema (HAE) is a disease manifested by repeated episodes of localized submucosal or subcutaneous edematous episodes, potentially triggered by emotional stress, mechanical trauma, or intake of estrogens. We present our experience managing two parturients with HAE. Multidisciplinary care is essential for planning and executing the specialized care of these patients, and management included extensive planning among obstetric, anesthesiology, and allergy and immunology teams. Pregnancy has been shown to have a variable effect on triggering HAE episodes. First-line treatment includes C1 esterase inhibitor concentrate, which can also be used for prophylaxis in high-risk patients. Neuraxial analgesia is recommended to avoid general anesthesia and was established early in both individuals. Vaginal delivery was well tolerated without need for emergent treatment for angioedema symptoms.
Klebsiella, Enterobacter , and Serratia : Biochemical Differentiation and Susceptibility to Ampicillin and Three Cephalosporin Derivatives
Zabransky, R.J., Hall, Jack W., Day, Fred E., Needham, Gerald M.

Mayo Clinic

Applied Microbiology | December 5, 2020 | Volume: 18 | Issue: 2 | Pages: 198-203

10.1128/am.18.2.198-203.1969 | PMID 4896880 Get It

Three hundred twenty-nine strains of the tribe Klebsielleae were compared by several biochemical tests and by susceptibility to selected antibiotics. Biochemical tests included urease, amino acid decarboxylase, and hydrogen sulfide production; fermentation of lactose and dextrose; motility; and tests in the IMViC (indole, methyl red, Voges-Proskauer, citrate) series. The isolates were: Klebsiella species, 67.5%; Enterobacter species, 28%, and Serratia species, 4.5%. Minimal inhibitory concentrations of cephaloridine, cephalothin, and a new cephalosporin, cephalexin, and of ampicillin were determined by the agar dilution procedure. Cephalosporins at 20 μg/ml or less inhibited 90% of the Klebsiella strains but only 15% of the Enterobacter strains. Ampicillin inhibited 27% of Enterobacter strains and 17% of Klebsiella strains. Serratia isolates were insensitive to the cephalosporins and ampicillin. The results suggest that precise identification of this group to the generic level can be accomplished readily in the clinical laboratory and that such information is helpful in the preliminary selection of an antibiotic for treatment of clinical infections.
Relationship of Clinician Care Team Composition and Diabetes Quality Outcomes
Meyerink, Benjamin D., Laabs, Susan, Foss, Randy , Garrison, Gregory M. , Angstman, Kurt B. , Sobolik, Gerald J. , Halasy, Michael , Fischer, Kristin , Rosas, Steven , Maxson, Julie, Rushlow, David , Horn, Jennifer L. , Matthews, Marc R. , Nagaraju, Darshan, Lampman, Michelle A. , Laabs, Susan B, Foss, Randy M, Halasy, Michael P, Fischer, Kristin J, Rosas, Steven L , Maxson, Julie A, Rushlow, David R, Thacher, Tom D. , Foss, Randy , Matthews, Marc R

Mayo Clinic

Population Health Management | November 20, 2020 | Volume: 24 | Issue: 4 | Pages: 502-508

10.1089/pop.2020.0229 | PMID 33216689 Get It

The objective was to determine if a greater proportion of physician full-time equivalent (FTE%) relative to nurse practitioners/physician assistants (NPs/PAs) on care teams was associated with improved individual clinician diabetes quality outcomes. The authors conducted a retrospective cross-sectional study of 420 family medicine clinicians in 110 care teams in a Midwest health system, using administrative data from January 1, 2017 to December 31, 2017. Poisson regression was used to examine the relationship between physician FTE% and the number of patients meeting 5 criteria included in a composite metric for diabetes management (D5). Covariates included panel size, clinician type, sex, years in practice, region, patient satisfaction, care team size, rural location, and panel complexity. Of the 420 clinicians, 167 (40%) were NP/PA staff and 253 (60%) were physicians. D5 criteria were achieved in 37.9% of NP/PA panels compared with 44.5% of physician panels ( P < .001). In adjusted analysis, rate of patients achieving D5 was unrelated to physician FTE% on the care team ( P = .78). Physicians had a 1.082 (95% confidence interval 1.007–1.164) times greater rate of patients with diabetes achieving D5 than NPs/PAs. Clinicians at rural locations had a .904 (.852-.959) times lower rate of achieving D5 than those at urban locations. Physicians had a greater rate of patients achieving D5 compared with NPs/PAs, but physician FTE% on the care team was unrelated to D5 outcomes. This suggests that clinician team composition matters less than team roles and the dynamics of collaborative care between members.
Dexamethasone and Lidocaine Suppress Eosinophilopoiesis from Umbilical Cord Blood Cells
Muraki, Masato , Gleich, Gerald J. , Kita, Hirohito

Mayo Clinic

No container title available | November 11, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-38041/v2 Get It

Abstract Background: Eosinophils play an important role in allergic inflammation. Glucocorticosteroids have been used as an anti-inflammatory medication for inflammatory diseases involving eosinophil infiltration. Some effect of nebulized lidocaine has been reported when treating certain patients with asthma, which is also an inflammatory disease. The goal of this study was to examine the effects of dexamethasone and lidocaine on eosinophil proliferation and differentiation using a model of human umbilical cord blood mononuclear cells (UCMC) cultured with IL-5. Methods: UCMC were cultured with IL-5 (5 ng/mL) for 4 weeks. The effects of dexamethasone and lidocaine on the number and morphology of eosinophilic cells were visualized with Wright-Giemsa and cyanide-resistant peroxidase stains. Moreover, the effect on eosinophil-derived neurotoxin (EDN) and eosinophil peroxidase (EPX) contents in cultured cells were evaluated using radioimmunoassay.Results: The number of eosinophilic cells and EDN and EPX content in cultured cells increased in a time-dependent manner in the presence of IL-5. Dexamethasone treatment slightly decreased the number of eosinophilic cells in one week, but this effect was lost in 2–4 weeks. Macrophages in cultured UCMC treated with dexamethasone contained more eosinophil granule proteins. Both EDN and EPX content in cultured cells were reduced by dexamethasone. Lidocaine decreased the number of eosinophilic cells and reduced both EDN and EPX contents in cultured cells.Conclusions: Dexamethasone suppressed the production of eosinophil granule proteins and may also induce apoptosis of eosinophils, while lidocaine suppresses eosinophilopoiesis.
Smooth Muscle Conditions of the Chest
McCann, Matthew R. , Massoth, Lucas R. , Rojas, Carlos A. , Hung, Yin P. , Lichtenberger, John P. , Abbott, Gerald F., Stowell, Justin T. , Hung, Yin P

Mayo Clinic

Journal of Thoracic Imaging | November 8, 2020 | Volume: 36 | Issue: 5 | Pages: 263-278

10.1097/rti.0000000000000567 | PMID 33165163 Get It

Smooth muscle conditions of the chest have diverse clinical and imaging manifestations and may involve nearly every thoracic structure. Differentiation among these conditions requires the integration of clinical, radiologic, and histopathologic data. Histologic examination in conjunction with immunohistochemistry is essential for differentiation from other spindle cell neoplastic mimics. Familiarity with these entities will ensure the inclusion of smooth muscle conditions in the differential diagnosis of thoracic soft tissue lesions and potentially guide the clinician in appropriate management. We review the clinical, imaging, and histopathologic features of thoracic smooth muscle-related conditions organized by the anatomic structures affected.
Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders
Kelemen, Katalin, Saft, Leonie , Craig, Fiona E. , Nakashima, Megan O. , Wertheim, Gerald , Horny, Hans-Peter, King, Rebecca L. , Wang, Sa A. , Reichard, Kaaren K. , Orazi, Attilio , George, Tracy I. , Quintanilla‐Martínez, Leticia , Rimsza, Lisa M.

Mayo Clinic

American Journal of Clinical Pathology | October 29, 2020 | Volume: 155 | Issue: 2 | Pages: 179-210

10.1093/ajcp/aqaa244 | PMID 33367563 Get It

AbstractObjectivesTo report the findings of the 2019 Society for Hematopathology/European Association for Haematopathology Workshop within the categories of reactive eosinophilia, hypereosinophilic syndrome (HES), germline disorders with eosinophilia (GDE), and myeloid and lymphoid neoplasms associated with eosinophilia (excluding entities covered by other studies in this series).MethodsThe workshop panel reviewed 109 cases, assigned consensus diagnosis, and created diagnosis-specific sessions.ResultsThe most frequent diagnosis was reactive eosinophilia (35), followed by acute leukemia (24). Myeloproliferative neoplasms (MPNs) received 17 submissions, including chronic eosinophilic leukemia, not otherwise specified (CEL, NOS). Myelodysplastic syndrome (MDS), MDS/MPN, and therapy-related myeloid neoplasms received 11, while GDE and HES received 12 and 11 submissions, respectively.ConclusionsHypereosinophilia and HES are defined by specific clinical and laboratory criteria. Eosinophilia is commonly reactive. An acute leukemic onset with eosinophilia may suggest core-binding factor acute myeloid leukemia, blast phase of chronic myeloid leukemia, BCR-ABL1–positive leukemia, or t(5;14) B-lymphoblastic leukemia. Eosinophilia is rare in MDS but common in MDS/MPN. CEL, NOS is a clinically aggressive MPN with eosinophilia as the dominant feature. Bone marrow morphology and cytogenetic and/or molecular clonality may distinguish CEL from HES. Molecular testing helps to better subclassify myeloid neoplasms with eosinophilia and to identify patients for targeted treatments.
Leveraging the Capabilities of the FDA’s Sentinel System To Improve Kidney Care
Adimadhyam, Sruthi , Frazee, Erin N. , Cocoros, Noelle M. , Brown, Jeffrey S. , Maro, Judith C. , Corrigan‐Curay, Jacqueline , Martin, David , Nguyen, Michael , Platt, Richard , Li, Xiaojuan , Maro, Judith C , Li, Xiaojuan , Toh, Sengwee , Pan, Gerald J. Dal , Ball, Robert

Mayo Clinic

Journal of the American Society of Nephrology | October 19, 2020 | Volume: 31 | Issue: 11 | Pages: 2506-2516

10.1681/asn.2020040526 | PMID 33077615 Get It

The Sentinel System is a national electronic postmarketing resource established by the US Food and Drug Administration to support assessment of the safety and effectiveness of marketed medical products. It has built a large, multi-institutional, distributed data network that contains comprehensive electronic health data, covering about 700 million person-years of longitudinal observation time nationwide. With its sophisticated infrastructure and a large selection of flexible analytic tools, the Sentinel System permits rapid and secure analyses, while preserving patient privacy and health-system autonomy. The Sentinel System also offers enhanced capabilities, including accessing full-text medical records, supporting randomized clinical trials embedded in healthcare delivery systems, and facilitating effective collection of patient-reported data using mobile devices, among many other research programs. The nephrology research community can use the infrastructure, tools, and data that this national resource offers for evidence generation. This review summarizes the Sentinel System and its ability to rapidly generate high-quality, real-world evidence; discusses the program’s experience in, and potential for, addressing gaps in kidney care; and outlines avenues for conducting research, leveraging this national resource in collaboration with Sentinel investigators.
The Predictive Role of Model for End‐Stage Liver Disease–Lactate and Lactate Clearance for In‐Hospital Mortality Among a National Cirrhosis Cohort
Mahmud, Nadim , Asrani, Sumeet K. , Ogola, Gerald , Kamath, Patrick S. , Serper, Marina , Asrani, Sumeet K , Serper, Marina , Kaplan, David E. , Taddei, Tamar H

Mayo Clinic

Liver Transplantation | October 7, 2020 | Volume: 27 | Issue: 2 | Pages: 177-189

10.1002/lt.25913 | PMID 33025731 Get It

The burden of cirrhosis hospitalizations is increasing. The admission Model for End‐Stage Liver Disease–lactate (MELD‐lactate) was recently demonstrated to be a superior predictor of in‐hospital mortality compared with MELD in limited cohorts. We identified specific classes of hospitalizations where MELD‐lactate may be especially useful and evaluated the predictive role of lactate clearance. This was a retrospective cohort study of 1036 cirrhosis hospitalizations for gastrointestinal bleeding, infection, or other portal hypertension–related indications in the Veterans Health Administration where MELD‐lactate was measured on admission. Performance characteristics for in‐hospital mortality were compared between MELD‐lactate and MELD/MELD‐sodium (MELD‐Na), with stratified analyses of MELD categories (≤15, >15 to <25, ≥25) and reason for admission. We also incorporated day 3 lactate levels into modeling and tested for an interaction between day 1 MELD‐lactate and day 3 lactate clearance. MELD‐lactate had superior discrimination for in‐hospital mortality compared with MELD or MELD‐Na (area under the curve [AUC] 0.789 versus 0.776 versus 0.760, respectively; P < 0.001) and superior calibration. MELD‐lactate had higher discrimination among hospitalizations with MELD ≤15 (AUC 0.763 versus 0.608 for MELD, global P = 0.01) and hospitalizations for infection (AUC 0.791 versus 0.674 for MELD, global P < 0.001). We found a significant interaction between day 1 MELD‐lactate and day 3 lactate clearance; heat maps were created as clinical tools to risk‐stratify patients based on these clinical data. MELD‐lactate had significantly superior performance in predicting in‐hospital mortality among patients hospitalized for infection and/or with MELD ≤15 when compared with MELD or MELD‐Na. Incorporating day 3 lactate clearance may further improve prognostication.
Occipital-Cervical Fusion and Ventral Decompression in the Surgical Management of Chiari-1 Malformation and Syringomyelia: Analysis of Data From the Park-Reeves Syringomyelia Research Consortium
CreveCoeur, Travis S. , Yahanda, Alexander T. , Maher, Cormac O. , Johnson, Gabrielle W. , Ackerman, Laurie L. , Adelson, P. David , Albert, Gregory W. , Aldana, Phillipp R, Alden, Tord D. , Anderson, Richard C. E. , Baird, Lissa , Bauer, David F. , Bierbrauer, Karin S. , Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel E., Daniels, David, Dauser, Robert C., Durham, Susan, Ellenbogen, Richard G. , Eskandari, Ramin , Fuchs, Herbert E., George, Timothy M., Greene, Stephanie , Gross, Naina L. , Guillaume, Daniel, Hankinson, Todd C. , Heuer, Gregory G. , Iantosca, Mark, Iskandar, Bermans J. , Jackson, Eric M. , Jea, Andrew, Johnston, James M. , Keating, Robert F., Kelly, Michael P. , Khan, Nickalus R. , Krieger, Mark D., Leonard, Jeffrey R. , Mangano, Francesco T. , Mapstone, Timothy B., McComb, J. Gordon , Muhlbauer, Michael S., Oakes, W. Jerry, Olavarria, Greg, O’Neill, Brent R., Park, Tae Sung, Ragheb, John , Shannon, Chevis N. , Smith, Jodi L. , Stone, Scellig , Strahle, Jennifer M. , Tamber, Mandeep S. , Torner, James C., Tuite, Gerald F. , Wait, Scott D. , Wellons, John C. , Whitehead, William E. , Limbrick, David D. , Torner, James C. , Kelly, Michael P , Yahanda, Alexander T , Ahmed, Raheel , Aldana, Phillip R., Grant, Gerald A. , Graupman, Patrick C. , Greenfield, Jeffrey P. , Guillaume, Daniel J, Haller, Gabe , Menezes, Arnold H. , Selden, Nathan R. W. , Shah, Manish N. , Shimony, Joshua S. , Limbrick, David D.

Mayo Clinic

Neurosurgery | September 22, 2020 | Volume: 88 | Issue: 2 | Pages: 332-341

10.1093/neuros/nyaa460 | PMID 33313928 Get It

Abstract BACKGROUND Occipital-cervical fusion (OCF) and ventral decompression (VD) may be used in the treatment of pediatric Chiari-1 malformation (CM-1) with syringomyelia (SM) as adjuncts to posterior fossa decompression (PFD) for complex craniovertebral junction pathology. OBJECTIVE To examine factors influencing the use of OCF and OCF/VD in a multicenter cohort of pediatric CM-1 and SM subjects treated with PFD. METHODS The Park-Reeves Syringomyelia Research Consortium registry was used to examine 637 subjects with cerebellar tonsillar ectopia ≥ 5 mm, syrinx diameter ≥ 3 mm, and at least 1 yr of follow-up after their index PFD. Comparisons were made between subjects who received PFD alone and those with PFD + OCF or PFD + OCF/VD. RESULTS All 637 patients underwent PFD, 505 (79.2%) with and 132 (20.8%) without duraplasty. A total of 12 subjects went on to have OCF at some point in their management (PFD + OCF), whereas 4 had OCF and VD (PFD + OCF/VD). Of those with complete data, a history of platybasia (3/10, P = .011), Klippel-Feil (2/10, P = .015), and basilar invagination (3/12, P < .001) were increased within the OCF group, whereas only basilar invagination (1/4, P < .001) was increased in the OCF/VD group. Clivo-axial angle (CXA) was significantly lower for both OCF (128.8 ± 15.3°, P = .008) and OCF/VD (115.0 ± 11.6°, P = .025) groups when compared to PFD-only group (145.3 ± 12.7°). pB-C2 did not differ among groups. CONCLUSION Although PFD alone is adequate for treating the vast majority of CM-1/SM patients, OCF or OCF/VD may be occasionally utilized. Cranial base and spine pathologies and CXA may provide insight into the need for OCF and/or OCF/VD.
Gerald J. Robbins, MD (1951-2015)
Solberg, Lawrence A. , Allen, Steven L.

Mayo Clinic

The Hematologist | September 3, 2020 | Volume: 12 | Issue: 4 | Pages: No page available

10.1182/hem.v12.4.4175 Get It